Patents by Inventor Abraham J. Langseth

Abraham J. Langseth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
    Patent number: 11819487
    Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 21, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Non-linear dosing of mirdametinib
    Patent number: 11806321
    Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 7, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Mirdametinib treatment
    Patent number: 11806322
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 7, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • MIRDAMETINIB TREATMENT
    Publication number: 20230321013
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF 1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: March 16, 2023
    Publication date: October 12, 2023
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
  • MIRDAMETINIB TREATMENT
    Publication number: 20230321014
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 12, 2023
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
  • NON-LINEAR DOSING OF MIRDAMETINIB
    Publication number: 20230293462
    Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
  • Treatment of cutaneous neurofibromas with Mirdametinib
    Publication number: 20230293463
    Abstract: The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth
  • MIRDAMETINIB TREATMENT
    Publication number: 20230293466
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: March 20, 2023
    Publication date: September 21, 2023
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB
    Publication number: 20230293472
    Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Uchenna H Iloejeo, Abraham J Langseth, Todd Shearer